Enteric viruses
Líneas de investigación
Content with Investigacion .
Virus entéricos
1. Vigilancia microbiológica y epidemiológica a nivel nacional de las infecciones causadas por enterovirus y parechovirus y de los casos de parálisis flácida aguda en menores de 15 años. Caracterización, asociación clínica y epidemiología molecular.
2. Investigación de los enterovirus y parechovirus que causan infecciones neurológicas y sistémicas severas en población pediátrica. Estudio de los factores virológicos implicados en la patogenicidad.
3. Estudio virológico de muestras ambientales (aguas residuales y tratadas para consumo) de la CAM.
4. Estudio virológico (diagnóstico y caracterización) de las infecciones gastrointestinales causadas por virus (norovirus, rotavirus y otros). Epidemiología molecular y caracterización de brotes.
Investigación y vigilancia de los poliovirus y la poliomielitis
El Laboratorio de Enterovirus (actualmente de Virus Entéricos) del CNM fue designado Laboratorio Nacional de Poliovirus en 1998 y desde entonces es certificado anualmente por la OMS, como parte del Plan Global de Erradicación de la Poliomielitis. Es responsable, junto a 3 laboratorios primarios en 3 CCAA, de la vigilancia de la poliomielitis a nivel nacional, estudiando e investigando (clínica, epidemiológica y virológicamente) todos los casos compatibles, incluidos los de parálisis flácida aguda en menores de 15 años (enfermedad de notificación obligatoria) para descartar la presencia y circulación de poliovirus en España.
Además, desde 1999 (y gracias a un convenio con el CYII) posee toda la infraestructura y metodología necesaria para realizar vigilancia medioambiental en aguas, tanto para medir la calidad de las aguas potables de ETAP, como para monitorizar la excreción de virus por parte de la población con el estudio de la presencia de poliovirus y otros enterovirus en aguas residuales de EDAR. Esto ha permitido que, a partir de marzo de este año, se estén realizando, además, ensayos de presencia de SARS-CoV-2 en las muestras procedentes de diferentes EDAR situadas en la CAM.
Investigación y referencia en infecciones por enterovirus y parechovirus
El Laboratorio también es Laboratorio de Referencia para las infecciones por Enterovirus y Parechovirus realizando: 1) el diagnostico virológico en muestras clínicas; 2) la caracterización de todos los enterovirus y parechovirus detectados (Programa de Vigilancia Microbiológica del CNM); 3) el desarrollo, mantenimiento y transferencia de métodos de diagnóstico y tipado, tanto moleculares como de cultivo viral; y 4) la investigación para profundizar en el conocimiento de aquellos virus implicados en casos de excepcional importancia clínica o epidemiológica. La larga experiencia del grupo en la propagación de cultivos virales de enterovirus y en técnicas celulares y moleculares de caracterización, ha permitido que el CNM posea una amplia colección de cepas, muy valiosa para la investigación de estos virus.
Investigación y referencia en infecciones gastrointestinales causadas por virus
Desde 2016, el laboratorio realiza: 1) el diagnostico virológico de Norovirus, Rotavirus, Adenovirus 40/41, Astrovirus y otros virus productores de gastroenteritis aguda en muestras clínicas; 2) el genotipado de los virus detectados y la caracterización de brotes; 3) el desarrollo y mantenimiento de métodos de diagnóstico y genotipado; y 4) la investigación básica y epidemiológica de aquellos virus de mayor importancia clínica.
Proyectos de investigación
Content with Investigacion .
Proyectos de investigación financiados en los últimos 5 años
- Investigación de las infecciones neurológicas graves en niños causadas por enterovirus emergentes en España: EV-A71 y EV-D68 (PI18CIII/00017). Financiación: ISCIII. 2019-2021. IP: M. Cabrerizo
- Metagenomic sequencing to identify viral etiologies in undiagnosed cases of meningitis and encephalitis (PI20CIII/00005). Financiación: ISCIII. 2021-2023. IP: M.D. Fernández-García
- Investigación en infecciones por enterovirus y parechovirus que causan patologías neurológicas y sistémicas graves en población infantil (PI15CIII/00020). Financiación: ISCIII. 2016-2019. IP: M. Cabrerizo
- Aplicación de la secuenciación masiva para el diagnóstico de infecciones neurológicas de origen vírico no filiadas (PI-0216-2019). Financiación: Junta de Andalucía, Consejería de Salud y Familias. 2019-2021. IP: M.D. Fernández-García (2019)/ Ana Belen Pérez-Jiménez (2020-21)
- Epidemiología y patogenia molecular de los enterovirus y parechovirus asociados a sepsis e infecciones neurológicas en población infantil en España (PI12/00904). Financiación: ISCIII. 2013-2016. IP: M. Cabrerizo
Otros proyectos de investigación relevantes en los que ha colaborado o colabora el grupo
- Dinámica de colonización e infección por E. coli enteroagregativo en poblaciones pediátricas y su asociación con la composición de la microbiota intestinal mediante análisis metagenómico (PI18CIII/00043). Financiación: ISCIII. 2019-2021. IP: S. Sánchez
- Paving the way for implementing a syndromic diagnostic scheme at the CNM for the diagnosis of diarrhoea-causing pathogens in stool samples based on molecular and metagenomics methods (PI19CIII/00029). Financiación: ISCIII. 2020-2022. IP: D. Carmena
- Engineering lactobacilli for intranasal immunization against the emerging enterovirus D68 (EV-D68) infections and prevention of acute flaccid myelitis. Financiación: ESCMID. 2019-2020. IP: M.C. Póvoa-Cabral
- Análisis epidemiológico y virológico de los agentes virales incluidos en la vacuna triple vírica: nuevos retos (PI15CIII/00023). Financiación: ISCIII. 2016-2019. IP: F. de Ory/A. Fernández
- Epidemiología general y molecular de la hepatitis E en España: ¿una zoonosis emergente? (PI080865). Financiación: ISCIII. 2009-2012. IP: M. Fogeda
- Etiología de las meningitis y encefalitis víricas en España (PI07/90154). Financiación: ISCIII. 2008-2010. IP: F. de Ory
- Investigation of the dynamics and geography of the spread of recombinant forms of human enteroviruses (WT081173MA). Financiación: Wellcome Trust. 2007-2010. IP: P. Simmonds.
Convenios
- Servicios para la realización de estudios virológicos previstos en el agua procedentes para Canal de Isabel II-Gestión (MVP-207/18). Financiación: Canal de Isabel II. 2018-2021. IP: M. Cabrerizo
- Análisis virológico en muestras de aguas procedentes del Canal de Isabel II (MVI-1005/99). Financiación: Canal de Isabel II. 2016-2017. IP: M. Cabrerizo
Publicaciones destacadas
HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study
Ryan P, Valencia J, Cuevas G; Troya J; Torres-Macho J; Muñoz-Gómez MJ, Muñoz-Rivas N, Canorea I, Vázquez-Morón S (‡), Resino S (‡ *). HIV screening and retention in care in people who use drugs in Madrid, Spain: A prospective study. Infect Dis Poverty. 2021; 10(1): 111. (A; FI= 10.49; D1, Tropical Medicine; JCR 2021). PMID: 34412695. DOI: 10.1186/s40249-021-00894-5.
PUBMEDObesity-related SNPs and weight gain following first-line antiretroviral therapy.
Berenguer J (*), Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, Roca C, González-García J, Dalmau D, Olalla J, Herrero C, Villarroya F, Domingo P, Resino S. Obesity-related SNPs and weight gain following first-line antiretroviral therapy. Clin Inf Dis. 2023; In press. (A; FI= 20.99; D1, Infectious Diseases; JCR 2021).
PUBMED DOIMild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study.
García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020). PMID: 31585189. DOI: 10.1016/j.jinf.2019.09.020.
PUBMEDEvaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M, Zaragoza O; CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. Clin Microbiol Infect. 2017 Jan;23(1):49.e1-49.e8.
PUBMED DOIIdentification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp
Rossi SA, de Oliveira HC, Agreda-Mellon D, Lucio J, Mendes-Giannini MJS, García-Cambero JP, Zaragoza O. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e01921-19. PMCID: PMC7179310.
PUBMED DOIParadoxical Growth of Candida albicans in the Presence of Caspofungin Is Associated with Multiple Cell Wall Rearrangements and Decreased Virulence
Rueda C, Cuenca-Estrella M, Zaragoza O. Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother. 2014;58(2):1071-83. PMCID: PMC3910852.
PUBMED DOIHCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients.
Brochado-Kith O, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A (‡), Jiménez-Sousa MA (‡), Resino S (‡ *). HCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients. Front immunol. 2021; 12:723196. (A; FI= 8.79; Q1, Immunology; JCR 2021). PMID: 34497613. DOI: 10.3389/fimmu.2021.723196.
PUBMEDCryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella
Trevijano-Contador N, Herrero-Fernández I, García-Barbazán I, Scorzoni L, Rueda C, Rossi SA, García-Rodas R, Zaragoza O. Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella. Virulence. 2015;6(1):66-74. PMCID: PMC4603429.
PUBMED DOIThe formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses
García-Barbazán I, Trevijano-Contador N, Rueda C, de Andrés B, Pérez-Tavárez R, Herrero-Fernández I, Gaspar ML, Zaragoza O. The formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses. Cell Microbiol. 2016 Jan;18(1):111-24.
PUBMED DOIPrevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey.
• Estirado Gómez A, Justo-Gil S, Limia A, Avellón A, Arce-Arnáez A, González-Rubio R, Diaz A, Del Amo J; Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey. Sci Rep. 2018 Jan 30;8(1):1858.
PUBMED DOIComparative Analysis of Aspergillus fumigatus Strains: The Reference Genome as a Matter of Concern.
Buitrago MJ, Martín-Gómez T. Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge. Front Microbiol. 2020 Mar 24; 11:467. doi: 10.3389/fmicb.2020.00467. eCollection 2020. PMID: 32269555.
PUBMED DOIIdentification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene.
Matamala N, Aggarwal N, Iadarola P, Fumagalli M, Gomez-Mariano G, Lara B, Martinez MT, Cuesta I, Stolk J, Janciauskiene S, Martinez-Delgado B. Identification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene. PLoS One. 2017 Jan 20;12(1):e0170533.
PUBMED DOISequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes.
Vega Y, Delgado E, de la Barrera J, Carrera C, Zaballos Á, Cuesta I, Mariño A, Ocampo A, Miralles C, Pérez-Castro S, Álvarez H, López-Miragaya I, García-Bodas E, Díez-Fuertes F, Thomson MM. Sequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes. PLoS One. 2016 Jun 29;11(6):e0158525.
PUBMED DOIY155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors
Perez-Sautu U, Pozo F, Cuesta I, Monzon S, Calderon A, Gonzalez M, Molinero M, Lopez-Miragaya I, Rey S, Cañizares A, Rodriguez G, Gonzalez-Velasco C, Lackenby A, Casas I. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors. Euro Surveill. 2014 Jul 10;19(27):14-20.
PUBMED DOIComparison of two highly discriminatory typing methods to analyze Aspergillus fumigatus azole resistance
Garcia-Rubio R, Escribano P, Gomez A, Guinea J, and Mellado E. Comparison of two highly discriminatory typing methods to analyze Aspergillus fumigatus azole resistance. Frontiers in Microbiology 2018. Jul 20;9:1626.
PUBMED DOIEvaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia.
Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M, Zaragoza O. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI. Clin Microbiol Infect. 2017 Jan; 23(1):49.e1-49.e8.
PUBMED DOIDevelopment and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus.
Bernal-Martínez L, Gil H, Rivero-Menéndez O, Gago S, Cuenca-Estrella M, Mellado E, Alastruey-Izquierdo A. Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01083-17.
PUBMED DOICervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS.
Nebreda T, Andres AG, Fuentes S, Calleja R, Jimenez MS. Cervicofacial lymphadenitis due Mycobacterium mantenii: rapid and reliable identification by MALDI-TOF MS. New Microbes and New Infections .2018. March 22:1-3.
PUBMED DOIIn-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain.
Sagasta S, Millan-Lou MI, Jiménez MS, Martin C, Samper S. In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain. Tuberculosis. 2016. Sep. 100:46-52.
PUBMED DOIGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016;60(1):6-13.
PUBMED DOICharacterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin
Garcia-Barreno B, Delgado T, Benito S, Casas I, Pozo F, Cuevas MT, et al. Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. J Gen Virol. 2014;95(Pt 5):1033-42.
PUBMED DOIA case of respiratory toxigenic diphtheria: Contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.
Jané, M., Vidal, M.J., Camps, N., Campins, M., Martínez, A., Balcells, J., Martin-Gomez, M.T., Bassets, G., Herrera-Leon, S., Foguet, A., Maresma, M., Follia, N., Uriona, S., Pumarola, T. A case of respiratory toxigenic diphtheria: Contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015. (2018) Eurosurveillance, 23 (13).
PUBMED DOIDevelopment of three multiplex PCR assays targeting the 21 most clinically relevant serogroups associated with Shiga toxin-producing E. coli infection in humans
Sánchez, S., Llorente, M.T., Echeita, M.A., Herrera-León, S. Development of three multiplex PCR assays targeting the 21 most clinically relevant serogroups associated with Shiga toxin-producing E. coli infection in humans (2015) PLoS ONE, 10 (1).
PUBMED DOIShiga toxin-producing Escherichia coli and atypical enteropathogenic E. coli infection in a Spanish household
Sánchez, S., Cenoz, M.G., Martín, C., Beristain, X., Llorente, M.T., Herrera-León, S. Cluster investigation of mixed O76:H19 Shiga toxin-producing Escherichia coli and atypical enteropathogenic E. coli infection in a Spanish household (2014) Epidemiology and Infection, 142 (5), pp. 1029-1033.
PUBMED DOIEpidemic history of hepatitis C virus genotypes and subtypes in Portugal.
Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Tato Marinho R, Borrego P, Taveira N. 2018. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018; 8:12266. (A; FI= 4.12; Q1 Multidisciplinary Sciences; DOI:10.1038/s41598-018-30528-0).
PUBMED DOILow frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.
Palladino C, Sanchez-Carrillo M, Mate-Cano I, Vazquez-Morón S, Jiménez-Sousa MA, Gutiérrez-Rivas M, Resino S, Briz V. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep. 2017; 7(1):2892. (A; FI= 4.12; Q1 Multidisciplinary Sciences).
PUBMED DOIOff-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice.
Palladino C, Navarro Gomez ML, Soler-Palacin P, Gonzalez-Tome MI, Jiménez de Ory S, Espiau M, Pérez-Hoyos S, León-Leal JA, Méndez M, Moreno-Pérez D, Fortuny C, uer A, Pocheville I, Moreno S, Briz V, on behalf of the CoRISpe Working Group. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. AIDS 2015; 29-16, pp.2155-2159. (A; FI= 4,407; Q1 Infectious Disease).
PUBMED DOIComparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection.
Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection. Avellon A, Morago L, Garcia-Galera del Carmen M, Munoz M, Echevarría JM. J Med Virol. 2015 Nov;87(11):1934-9. Epub 2015 May 29.
PUBMED DOIRelative telomere length impact on mortality of COVID-19: sex differences.
Virseda-Berdices A, Concostrina-Martinez L, Martínez-González O, Blancas R, Resino S, Ryan P, De Juan C, Moreira-Escriche P, Martin-Vicente M, Brochado-Kith O, Blanca-López N, Jiménez-Sousa MA (‡,*), Fernández-Rodríguez A (‡). Relative telomere length impact on mortality of COVID-19: sex differences. J Med Virol 2023; 98 (1): e28368 (A; FI= 20.96; D1, Virology; JCR 2021).
PUBMEDActivity of host antimicrobials against multidrug resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide
García-Quintanilla, M., Pulido, M. R., Moreno-Martínez, P., Martín-Peña, R., López-Rojas, R., Pachón, J. and McConnell, M.J.* Activity of host antimicrobials against multidrug resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrobial Agents and Chemotherapy 2014. May;58(5):2972-5.
PUBMED DOIPlasma miRNA profile at COVID-19 onset predicts severity status and mortality.
Fernández-Pato A; Virseda-Berdices A, Ryan P; Martínez-González O, Peréz-García F, Resino S, Martin-Vicente M, Valle-Millares D, Brochado-Kith O; Blancas R; Ceballos FC; Bartolome-Sánchez S; Vidal-Alcántara EJ; Alonso-Menchén D, Blanca-López N; Ramirez Martinez-Acitores I, Rava M, Jiménez-Sousa MA (‡ *), Amanda Fernández-Rodríguez (‡ *). Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerg Microbes Infect 2022; 11(1):676-688 (A; FI= 19.57; D1, Infectious Diseases; JCR 2021).
PUBMED DOIMild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study.
García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020).
PUBMED DOIEfficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease
Buitrago MJ, Aguado JM, Ballen A, Bernal-Martinez L, Prieto M, Garcia-Reyne A, Garcia-Rodriguez J, Rodriguez-Tudela JL, Cuenca-Estrella M. Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. Clin Microbiol Infect. 2013 Jun;19(6):E271-7. doi: 10.1111/1469-0691.12110. Epub 2013 Mar 7. PMID: 23464751.
PUBMED DOIAn alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains
15. Alcazar-Fuoli L, Buitrago M, Gomez-Lopez A, Mellado E. An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains. Virulence. 2015;6(4):376-84. doi: 10.1080/21505594.2015.1025192. PMID: 26065322.
PUBMED DOINationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era
de Miguel S, Domenech M, González-Camacho F, Sempere J, Vicioso D, Sanz JC, Comas LG, Ardanuy C, Fenoll A, Yuste J. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era. Clin Infect Dis. 2021 Dec 6;73(11):e3778-e3787
PUBMED DOIPulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis
7. Mata E, Tarancón R, Guerrero C, Moreo E, Moreau F, Uranga S, Gomez AB, Marinova D, Domenech M, Gonzalez-Camacho F, Monzon M, Badiola J, Dominguez-Andres J, Yuste J, Anel A, Peixoto A, Martin C, Aguilo N. Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. Sci Immunol. 2021 Sep 24;6(63):eabc2934
PUBMED DOIVaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System
Corsini B, Aguinagalde L, Ruiz S, Domenech M, Yuste J. Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System. Vaccines. 2021 Feb 23;9(2):186.
PUBMED DOIContent with Investigacion .
-
María Cabrerizo Sanz
Tenure Scientist and Group Leader
ORCID code: 0000-0001-7054-5696
Doctor in Chemistry, specializing in Biochemistry and Molecular Biology, Universidad Autónoma de Madrid (2000). Except for a postdoctoral period of 2 years at the Hospital de La Princesa, in which her research was related to onco-hematological diseases, the rest of her scientific career has focused on the study of infectious diseases caused by viruses and their surveillance. She joined the Instituto de Salud Carlos III in 2003, first in the Laboratory of Arbovirus and Imported Viral Diseases, then in the Laboratory of Viral Hepatitis and finally, in the Laboratory of Enterovirus (which is accredited as a National Polio Laboratory -LNP- for the WHO since 1998). She obtained the position of Tenure Scientist in 2016, at the same time she assumed the responsibility of the laboratory, currently of Enteric Viruses: Poliovirus/Enterovirus, Parechovirus and Gastroenteritis-producing Viruses, of the CNM. She has 4 scientific sexennials and 4 quinquennials recognized.
She has been and is PI of 4 consecutive research projects and 3 service contracts, from 2012 to the present, participating, in addition, in other 20 projects. As head of the LNP, she is part of the Working Group of the National Plan for the Eradication of Poliomyelitis and of the WHO European Polio Laboratory Network. She is also a member of the European Non-Polio Enterovirus Network (ENPEN), and of the national cooperation networks CIBERESP and RITIP (IdiPAZ). Since 2023 she is a Council Member from Spain of the European Society.
In total she has published 98 articles in WoS indexed journals (23 Q1 and 22 D1), being first author, senior author or correspondence author in 43 of them (H=27). She has supervised 1 PhD Thesis (2017) and 12 TFM. She is currently supervising another doctoral thesis (IMIENS-UNED). She participates as a teacher in three university masters (UCM, UAH and UV), being coordinator of the subject H2 of the Master of Virology at UCM.
-
Mª Dolores Fernández García
Tenure Scientist
ORCID code: 0000-0003-0336-6596
Degree in Pharmacy (2005) and PhD from the University VII Paris Diderot in Microbiology (2010). She completed her doctoral thesis at the Pasteur Institute in Paris characterizing the molecular and cellular basis of flavivirus entry into cells. Specialist in Public Health Microbiology (European Program EUPHEM coordinated by ECDC). She has worked 3 years for the French Ministry of Foreign Affairs as a researcher at the Pasteur Institute in Dakar (Senegal) carrying out microbiological surveillance activities and research on polioviruses and non-polio enteroviruses in West Africa. She has obtained two Miguel Servet contracts: one to work at IMIBIC in Cordoba (2019) and an intramural one to work at CNM (2020). Both were awarded for the study of neurotropic viruses applying massive sequencing for their diagnosis. In 2021 he joined the CNM-ISCIII as a Tenure Research Scientist at the Enterovirus and Viral Gastroenteritis Unit of the CNM-ISCIII. Since then, she combines her scientific activity with the assistance to the National Health System in the microbiological research of outbreaks and in the Genomic Surveillance of Enteroviruses and Gastroenteritis-producing Viruses.
She is a researcher in the Epidemiology and Public Health Area of the Centro de Investigación Biomédica en Red (CIBERESP-ISCIII). In addition, she is an evaluator and panelist for the HORIZON health program projects of the European Commission, the French National Agency ANRS-Emerging Infectious Diseases, R&D&I in HEALTH of the Strategic Action in Health (ISCIII) and the Andalusian Public Foundation Progreso y Salud. She has worked as scientific advisor to the Spanish Ministry of Health on Rotavirus and Polio. Since 2020 she has been teaching virology in different Spanish universities.
She has worked for WHO in the investigation of numerous outbreaks caused by viruses (Ebola, Zika, Yellow Fever, Dengue, etc.) in African and Asian countries strengthening laboratory capacities through technology transfer of diagnostic methods, training of laboratory personnel in these countries and scientific advisory tasks to the Ministries of Health. She has been the Health Coordinator of the START Project (Spanish Technical Aid Response Team) of the AECID, framed in the “Emergency Medical Teams” initiative of the WHO, participating in the establishment for Spain of a field hospital classified by the WHO as EMT Level 2 for interventions in humanitarian emergencies.
-
Carmen Serrano Risquez
Investigador predoctoral (CAM)
-
Juan Camacho Padilla
Investigador predoctoral (PFIS)
-
Yasmin Biya Assiry
Técnico de laboratorio en formación (PEJ-CAM)
-
Estrella Ruiz de Pedro
Técnico de laboratorio (PTA para Infraestructuras de I+D+I)
-
Rubén González Sanz
Técnico Superior Especializado OPI
-
Clara Martín Martín
Investigador predoctoral (PFIS)
-
Nazaret Díaz Sánchez
Técnico Superior Especializado OPI (apoyo)
-
Nerea García Ibáñez
Ayudante de Investigación de OPI. Técnico de laboratorio
-
Vanesa Recio Huertas
Ayudante de Investigación de OPI. Técnico de laboratorio (apoyo)
-
Ana Donoso Almenara
Contratada predoctoral pFIS
List of staff
Información adicional
This group constitutes the National Poliovirus Laboratory (Polio Eradication Plan), integrated into the European network WHO/EURO Polio Laboratory Network and coordinating, in turn, the National Network of Laboratories for the study of paralysis cases in Research on enterovirus and parechovirus infections in the pediatric population has been funded since 2013 through research projects (PI PI12/00904; PI15CIII/00020; PI18CIII/00017), of which María Cabrerizo is PI and in which epidemiologists (CNE) and pediatricians and microbiologists from more than 20 SNS hospitals participate.
The PI belongs to the consolidated research group RITIP-IdiPaz and CIBERESP. Since 1999, the group has been carrying out the virological study of environmental samples (wastewater and treated water) from the CAM, through a contract with the CYII. Finally, the group is responsible for the diagnosis and characterization of gastrointestinal infections caused by viruses (norovirus, rotavirus and others) and for the investigation of outbreaks (CS of the CNM).
This group constitutes the National Poliovirus Laboratory (Polio Eradication Plan), integrated into the European network WHO/EURO Polio Laboratory Network and coordinating, in turn, the National Network of Laboratories for the study of paralysis cases in Research on enterovirus and parechovirus infections in the pediatric population has been funded since 2013 through research projects (PI PI12/00904; PI15CIII/00020; PI18CIII/00017), of which María Cabrerizo is PI and in which epidemiologists (CNE) and pediatricians and microbiologists from more than 20 SNS hospitals participate.
The PI belongs to the consolidated research group RITIP-IdiPaz and CIBERESP. Since 1999, the group has been carrying out the virological study of environmental samples (wastewater and treated water) from the CAM, through a contract with the CYII. Finally, the group is responsible for the diagnosis and characterization of gastrointestinal infections caused by viruses (norovirus, rotavirus and others) and for the investigation of outbreaks (CS of the CNM).